文献速递临床试验与 GCP基础与转化研究

TREAT EARLIER:早期关节痛干预逆转或限制类风湿关节炎加重的随机双盲安慰剂对照临床试验方案

TREAT Early Arthralgia to Reverse or Limit Impending Exacerbation to Rheumatoid arthritis (TREAT EARLIER): a randomized, double-blind, placebo-controlled clinical trial protocol.
PubMed 文献 · Trials · 2020-10-16

TREAT EARLIER是一项随机双盲安慰剂对照试验方案,旨在验证在临床关节炎前的症状期(临床可疑关节痛,CSA)进行干预能否阻止亚临床炎症进展为持续性临床关节炎。研究拟从荷兰西南部二级医院招募230例CSA且手/足关节1.5T MRI显示亚临床炎症的患者,随机接受单次肌注120 mg甲泼尼龙后口服甲氨蝶呤(递增至25 mg/周)或安慰剂治疗1年,再随访1年。主要终点为发生符合2010年RA标准或≥2个关节的未分类临床关节炎并持续至少2周,无DMARD状态为共同主要终点。

要点

  • 纳入标准为CSA且近1年内起病、治疗风湿科医生判断有进展为RA风险,并需手/足关节1.5T MRI显示亚临床炎症。
  • 干预为单次肌注120 mg甲泼尼龙后口服甲氨蝶呤递增至25 mg/周,或安慰剂,疗程1年,随后随访1年。
  • 主要终点为持续至少2周的临床可检测关节炎(符合2010年RA标准或≥2个关节未分类关节炎),无DMARD状态为共同主要终点。

核心结论

  • 该方案将检验在临床关节炎前的症状期使用甲氨蝶呤干预能否阻止持续性RA的发生并减轻疾病负担。

研究设计与样本

  • 随机、双盲、安慰剂对照临床试验方案,计划从荷兰西南部二级医院招募230例 participant。
  • 患者需满足CSA且近1年内起病、疑似进展为RA,并手/足关节1.5T MRI显示亚临床炎症。
  • 干预组接受单次肌注120 mg甲泼尼龙后口服甲氨蝶呤递增至25 mg/周,对照组接受安慰剂注射和片剂,疗程1年,随后随访1年。

关键数值与推荐

  • 主要终点为发生符合2010年RA标准或≥2个关节的未分类临床关节炎并持续至少2周。
  • 无DMARD状态为共同主要终点。
  • 患者报告的功能、工作能力和症状为关键次要终点。

临床怎么用

  • 该研究为概念验证性试验,结果尚未报告,暂不能直接指导临床实践。

局限性

  • 本文为研究方案,尚未提供干预效果数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We present a study protocol for a randomized, double-blind, placebo-controlled trial that investigates the hypothesis if intervention in the symptomatic phase preceding clinical arthritis (clinically suspect arthralgia (CSA)) is effective in preventing progression from subclinical inflammation to clinically apparent persistent arthritis. Currently, rheumatoid arthritis (RA) can be recognized and diagnosed when arthritis (joint swelling) has become detectable at physical examination. Importantly, at this time, the immune processes have already matured, chronicity is established, and patients require long-standing treatment with disease-modifying anti-rheumatic drugs. The TREAT EARLIER trial studies the hypothesis that intervention in the symptomatic phase preceding clinical arthritis is more often successful in permanent disease modification because of less matured underlying disease processes. METHODS: A two-level definition to identify patients that are prone to develop RA is used. First, patients should have CSA and recent-onset arthralgia (< 1 year) that is suspect to progress to RA according to the expertise of the treating rheumatologist. Second, patients need to have subclinical inflammation of the hand or foot joints at 1.5 T MRI. The trial aims to recruit 230 participants from secondary care hospital settings across the south-west region of The Netherlands. Intervention will be randomly assigned and includes a single-dose of intramuscular 120 mg methylprednisolon followed by methotrexate (increasing dose to 25 mg/week orally) or placebo (both; injection and tablets) over the course of 1 year. Thereafter, participants are followed for another year. The primary endpoint is the development of clinically detectable arthritis, either fulfilling the 2010 criteria for RA or unclassified clinical arthritis of ≥ 2 joints, which persists for at least 2 weeks. DMARD-free status is a co-primary endpoint. The patient-reported outcomes functioning, along with workability and symptoms, are key secondary endpoints. Participants, caregivers (including those assessing the endpoints), and scientific staff are all blinded to the group assignment. DISCUSSION: This proof-of-concept study is the logical consequence of pre-work on the identification of patients with CSA with MRI-detected subclinical joint inflammation. It will test the hypothesis whether intervention in patients in this early phase with the cornerstone treatment of classified RA (methotrexate) hampers the development of persistent RA and reduce the disease burden of RA. TRIAL REGISTRATION: Dutch Trial Register NL4599 (NTR4853). Registered on 20 October 2014.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Niemantsverdriet E, Dakkak YJ, Burgers LE, et al. TREAT Early Arthralgia to Reverse or Limit Impending Exacerbation to Rheumatoid arthritis (TREAT EARLIER): a randomized, double-blind, placebo-controlled clinical trial protocol. Trials. 2020. PMID: 33076964. doi:10.1186/s13063-020-04731-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。